The pipeline of acne therapeutics is packed with possibilities, but of four candidates to report data so far this year, only one was successful – Allergan's and Paratek's sarecycline, which may be a better antibiotic option, but doesn't give dermatologists a much-needed new mechanism of action.

Brief profiles of these recently formed companies: 3D Biomatrix, IDx, InControl Medical and Intrepid Therapeutics.

Boston Scientific touts stent wins. Biomet settles foreign bribery charges. Roche ups Illumina bid. Derma Sciences acquires MedEfficiency.

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions